At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed non-small-cell lung cancer
- ✓Inoperable stage I–II or unresectable stage IIIA–IIIB disease per AJCC 1998 criteria
- ✓Primary tumor must be radiographically measurable
- ✓Age >18
- ✕Small cell carcinoma or mesothelioma
- ✕Medical contraindication to chemotherapy or radiotherapy
- ✕Myocardial infarction within preceding 6 months or symptomatic heart disease (uncontrolled/unstable angina, congestive heart failure, arrhythmia)
- ✕Pregnant women
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers
In Brief
A Phase 2 clinical trial evaluating Paclitaxel and Radiation Therapy for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 41 participants across 1 site.
Detailed Summary
A treatment study is being conducted by the University of Rochester Cancer Center (URCC) in which patients with non-small cell lung cancer will be treated with radiation therapy and a drug called paclitaxel. Paclitaxel is a natural product with anticancer properties. The first purpose of this study is to determine the dose of paclitaxel which, when given in combination with radiation therapy, will provide the greatest effect have the least side effects. To determine this, patients will be put on the study in groups of 3. The dose for each additional group will be higher than the previous dose until the maximum tolerated dose is reached. The second purpose is to determine if radiation therapy with paclitaxel is more effective in treating lung cancer than radiation therapy alone.
Study Details
Timeline
Interventions
On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible